Evaluation of an Experimental Vaccine for Atrophic Rhinitis in Piglets
Journal Title: UNKNOWN - Year 2017, Vol 8, Issue 1
Abstract
Background: Commercial swine atrophic rhinitis (AR) vaccine contains killed Bordetella bronchiseptica and P. multocida toxin (PMT) from Toxigenic Pasteurella multocida. The recombinant PMT proteins used as vaccine candidates were seldom reported. Methods: In this study, we developed recombinant fragments of PMT to replace P. multocida toxin in AR vaccine to compare the efficacy of this vaccine candidate with the commercial vaccine. Results: The experimental AR vaccine showed similar efficacy after bacterial challenges since there were no significant differences in clinical symptoms, turbinate lesions, lung lesions and daily body gain between the two vaccinated groups. Discussion and conclusion: The replacement of recombinant fragments of PMT to P. multocida toxin in AR vaccine provided same protection as commercial vaccine after bacterial challenges. However, high yield and simple processing of recombinant fragments of PMT from E.coli cells to replace purified P. multocida toxin in AR vaccine will dramatically reduce the cost of vaccines and simplify the antigen preparation.
Authors and Affiliations
Shijiang Gu, Yangyang Fan, Dongbo Hu, Xiangdong Li, Wuping Peng, Yonghong Liao, Kegong Tian
Keywords
Related Articles
- EP ID EP361409
- DOI 10.4172/2157-7560.1000353
- Views 30
- Downloads 0
Age to End Dreadful Diseases (HIV, Malaria, TB, Cancer and More): A Theory of Intact or Protected Complement (IPC) Immunity
After enormous efforts to fight for a successful HIV vaccine, the movement ended with frustration. While people are celebrating the victories of disease prophylaxis and healthy improvement, millions of them are still str...
Evaluation of an Experimental Vaccine for Atrophic Rhinitis in Piglets
Background: Commercial swine atrophic rhinitis (AR) vaccine contains killed Bordetella bronchiseptica and P. multocida toxin (PMT) from Toxigenic Pasteurella multocida. The recombinant PMT proteins used as vaccine candid...
MEFA (multiepitope fusion antigen) - Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA
Vaccine development often encounters the challenge of virulence heterogeneity. Enterotoxigenic Escherichia coli (ETEC) bacteria producing immunologically heterogeneous virulence factors are a leading cause of children’s...
Development of an in vitro Biochemical Assay System for the Measurement of Residual Toxin Activities in Pertussis Toxin Containing Vaccines
Pertussis (whooping cough) vaccines play an essential role in immunisation programmes worldwide and the histamine sensitisation test (HIST) is currently the official batch-release test for acellular pertussis containing...
Fractional Delivery: Toward a Painless, Safe and Effective Cutaneous Vaccination
Delivering vaccines into skin (Cutaneous Vaccination) is one of most promising strategies for the next generation vaccination. Cutaneous vaccination enables high vaccination efficacy harnessing the unique immunological n...